Prodotti competitors / Area Oncology
Capivasertib (Truqap): delays in Phase 1b/3 CAPItello-290 trial evaluating capivasertib + CDK4/6i + fulvestrant in HR+/HER2- metastatic breast cancer
AstraZeneca delayed the Primary Complition Date and Sickle Cell Disease of the Phase 1b/3 CAPItello-290 trial evaluating capivasertib (Truqap; AKTi) + CDK4/6i + fulvestrant in 1L+ ET resistant HR+/HER2- mBC by 15mo and 9mo, respectfully.
Grazie per il tuo feedback!